Clinical trials: Hemodialysis
Renal Failure Chronic Requiring Hemodialysis
A Pilot Study of a Heparin Dosing Algorithm for Hemodialysis
During hemodialysis treatments, patients receive heparin to prevent clotting. The purpose of this pilot study is to determine if the amount of heparin administered during a patient's hemodialysis can be individualized using an…
- Trial name
- NCT01181544
- Testing
- Heparin dose titration
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Vantive Health LLC
Anemia in Chronic Kidney Disease
Effect of Hemodialysis on the PK of JTZ-951 in Subjects With End-stage Renal Disease
The purpose of this study is to evaluate the effect of hemodialysis on the pharmacokinetics (PK) of JTZ-951 and to evaluate the safety of 2 doses of JTZ-951 in subjects with end-stage renal disease (ESRD) receiving hemodialysis
- Trial name
- NCT01978587
- Testing
- JTZ-951
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Shionogi Inc.
Hemodialysis Subjects With Secondary Hyperparathyroidism
A Mass Balance Study of [14C] MT1013 in Hemodialysis Subjects With Secondary Hyperparathyroidism
MT1013 is a first-in-class dual-target agonist.This study is being conducted to determine the mass balance and routes of excretion of total radioactivity after the dose of [14C] MT1013.
- Trial name
- NCT07284043
- Testing
- [14C] MT1013/MT1013 Injection
- Where
- China
- Volunteers
- 6 people
- Sponsor
- Shaanxi Micot Pharmaceutical Technology Co., Ltd.
End Stage Kidney Disease
The Vascutek Rapidax™ II Post Market Surveillance Registry
Multicentre, prospective, observational post-market registry. To monitor and collect data on the post-market clinical safety and performance of the Vascutek Rapidax II Vascular Access Graft.
- Trial name
- NCT01977508
- Testing
- ePTFE vascular access grafts
- Where
- 3 sites in Germany
- Volunteers
- 24 people
- Sponsor
- Vascutek Ltd.
Chronic Renal Failure, Chronic Kidney Disease
A Phase 3 Study Comparing the Effects of Subcutaneous Epoetin Hospira and Epoetin Alfa [Epogen] (Amgen) in Patients With Chronic Renal Failure Requiring Hemodialysis and Receiving Epoetin Maintenance Treatment. AiME - Anemia Management With Epoetin
The purpose of this study is to demonstrate therapeutic equivalence of subcutaneous (SC) Epoetin Hospira compared to SC Epogen (Amgen), based on maintenance of hemoglobin (Hb) levels and study drug dose requirements in patients…
- Trial name
- AiME - 13 (NCT01473420)
- Testing
- Epoetin Hospira, Epogen Amgen
- Where
- 73 sites in United States
- Volunteers
- 320 people
- Sponsor
- Pfizer
Hemodialysis Patients
Detection of Lung Pathologies Among Dialysis Patients Using Pulsenmore MC™ Device - Feasibility Study
PRIMARY OBJECTIVE: To measure success rate and identification of pathological lung B-lines, using novel mobile Self-scan ultrasound device (MC, by Pulsenmore), in chronic renal failure patients, pre and post dialysis.
- Trial name
- NCT07028060
- Testing
- PulseNmore MC™
- Where
- Israel
- Volunteers
- 10 people
- Sponsor
- PulseNmore
End Stage Renal Disease
A Multiple-Dose Study of Oral Oseltamivir in Participants on Hemodialysis (HD) and Continuous Ambulatory Peritoneal Dialysis (CAPD)
This study is designed to assess the pharmacokinetics (PK) and safety of oseltamivir and its metabolite oseltamivir carboxylate in participants undergoing routine HD and CAPD for end-stage renal disease (ESRD).
- Trial name
- NCT02617784
- Testing
- Oseltamivir
- Where
- New Zealand
- Volunteers
- 24 people
- Sponsor
- Hoffmann-La Roche
End Stage Renal Disease
Evaluating Aranesp® in Subjects With End Stage Renal Disease onChronic Hemodialysis
The purpose of this study is to assess the Aranesp® dose administered intravenously (IV) once weekly to maintain hemoglobin (Hgb) levels in hemodialysis subjects who are either recombinant human erythropoietin (rHuEPO) naïve or…
- Trial name
- NCT00117104
- Testing
- Aranesp®
- Sponsor
- Amgen
Kidney Failure, Chronic, Renal Dialysis
Renal Denervation in End Stage Renal Disease Patients With Refractory Hypertension
The purpose of this this study is to investigate the clinical utility of renal denervation in the treatment of ESRD patients with refractory hypertension.
- Trial name
- NCT00753116
- Testing
- Renal Denervation with a catheter-based procedure
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Medtronic Vascular
Secondary Hyperparathyroidism
A Phase 3 Study of Etelcalcetide in Children With Secondary Hyperparathyroidism Receiving Hemodialysis
Assess the efficacy, safety, pharmacokinetics (PK) and pharmacodynamics (PD) of etelcalcetide in the treatment of secondary hyperparathyroidism (SHPT) in pediatric participants between ≥ 2 to < 18 years of age, with chronic…
- Trial name
- NCT03969329
- Testing
- Etelcalcetide
- Where
- 23 sites in Belgium, Czechia and 10 more
- Volunteers
- 24 people
- Sponsor
- Amgen
Hyperparathyroidism
Phase 1/2 Study of KHK7580 for Secondary Hyperparathyroidism in Patients Receiving Hemodialysis
This study is designed to evaluate safety, pharmacokinetics and pharmacodynamics after single and multiple administration of KHK7580 for secondary hyperparathyroidism in patients receiving hemodialysis
- Trial name
- NCT01935856
- Testing
- KHK7580
- Where
- Japan
- Volunteers
- 20 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Anemia, Iron-Deficiency
A Two-part Single- and Repeat-dose Study of CSJ137 in Anemic Chronic Hemodialysis Patients
The study will assess the safety, tolerability and efficacy of CSJ137 in chronic hemodialysis patients. It is hypothesized that treatment with CSJ137 may improve the level of hemoglobin in patients on chronic hemodialysis with…
- Trial name
- NCT02570854
- Testing
- CSJ137
- Where
- 13 sites in United States, Czechia and 2 more
- Volunteers
- 40 people
- Sponsor
- Novartis Pharmaceuticals
Renal Failure Chronic Requiring Hemodialysis
Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients
The purpose of this study is to confirm the safety and efficacy of Soluble Ferric Pyrophosphate (SFP) dialysate solution in maintaining iron delivery for erythropoiesis in anemic adult patients with chronic kidney disease (CKD)…
- Trial name
- CRUISE 1 (NCT01320202)
- Testing
- Soluble Ferric Pyrophosphate (SFP), Standard dialysate
- Where
- 47 sites in United States, Puerto Rico
- Volunteers
- 305 people
- Sponsor
- Rockwell Medical Technologies, Inc.
End Stage Renal Disease (ESRD)
To Compare the Efficacy and Safety of the ATEV With AVF in Female Patients With End-Stage Renal Disease Requiring Hemodialysis
The goal of this clinical trial is to compare the number of catheter-free days (CFD) and the rate and severity of any dialysis access-related infections between the ATEV and AVF groups over 12 months in patients with end-stage…
- Trial name
- NCT05908084
- Testing
- Acellular Tissue Engineered Vessel (ATEV), AVF
- Where
- 32 sites in United States
- Volunteers
- 121 people
- Sponsor
- Humacyte, Inc.
Hemodialysis Patients With Renal Anemia
A Long Term Study of Intermittent Oral Dosing of ASP1517 in Hemodialysis Chronic Kidney Disease Patients With Anemia Converted From Erythropoieses Stimulating Agent (ESA) Treatment
The objective of this study is to evaluate the efficacy and safety of ASP1517 in hemodialysis patients with renal anemia whose treatment is converted from an Erythropoieses Stimulating Agent formulation.
- Trial name
- NCT02779764
- Testing
- roxadustat
- Where
- 25 sites in Japan
- Volunteers
- 164 people
- Sponsor
- Astellas Pharma Inc
Hyperphosphatemia Patients on Hemodialysis
A Phase 2 Dose-finding Study of TS-172 in Hyperphosphatemia Patients on Hemodialysis
A phase 2, randomized, placebo-controlled, double-blind, dose-finding study of TS-172 in hyperphosphatemia patients on hemodialysis
- Trial name
- NCT05699239
- Testing
- TS-172 10mg bid, TS-172 30mg bid, TS-172 60mg bid
- Where
- Japan
- Volunteers
- 326 people
- Sponsor
- Taisho Pharmaceutical Co., Ltd.
Carcinoma, Renal Cell
Study of Orellanine in Metastatic Clear-Cell or Papillary Renal Cell Carcinoma
A phase I/II, open-label, study to determine the safety and preliminary efficacy of orellanine in patients with metastatic clear-cell or papillary renal carcinoma who have failed standard-of-care therapy.
- Trial name
- NCT05287945
- Testing
- Orellanine
- Where
- 10 sites in United States, France and 3 more
- Volunteers
- 75 people
- Sponsor
- Oncorena AB
Renal Dialysis, Pharmacokinetics
A Single Dose Study Investigating The Elimination Of PD-0332334 In Patients Receiving Regular Hemodialysis
1. Quantify how much PD-0332334 is removed from the blood with hemodialysis 2. Investigate the pharmacokinetics of a single dose of PD-0332334 in subjects receiving regular hemodialysis treatments. 3.
- Trial name
- NCT00730145
- Testing
- PD-0332334
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- Pfizer
End Stage Renal Disease, End Stage Renal Failure on Dialysis
First-in-Human (FIH) Study of the Xeltis Hemodialysis Access Graft
A feasibility study is to assess the preliminary safety and performance of the Xeltis hemodialysis access (aXess) graft.
- Trial name
- aXess-FIH (NCT04898153)
- Testing
- aXess
- Where
- 6 sites in Belgium, Italy and 2 more
- Volunteers
- 20 people
- Sponsor
- Xeltis
Kidney Disease, Chronic
An Observational Study of Mircera (Methoxy Polyethylene Glycol-epoetin Beta) in Patients With Chronic Kidney Disease Not On Dialysis
This observational, prospective, multicenter study will describe the mean dose of Mircera (methoxy polyethylene glycol-epoetin beta) and the hemoglobin levels in patients with chronic kidney disease.
- Trial name
- NCT01318512
- Where
- Czechia
- Volunteers
- 340 people
- Sponsor
- Hoffmann-La Roche